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Outcomes in Patients
With Heart Failure With
Preserved Ejection Fraction
It Is More Than the Heart*
Dalane W. Kitzman, MD
Winston-Salem, North Carolina
In this issue of the Journal, Ather et al. (1) report on the
mpact of noncardiac comorbidities on outcomes in patients
ith heart failure (HF) with preserved ejection fraction
HFpEF). Their findings are credible, important, and
imely. HFpEF is the most common form of HF in the
opulation, is dominant among the elderly, and is increasing
ut of proportion to HF with reduced ejection fraction
HFrEF), and its prognosis is worsening, while that of
FrEF is improving. The pathophysiology of HFpEF is
ncompletely understood, and the few clinical trials to date
ave been negative, such that there are few evidence-based
reatments to improve outcomes. It has become clear that
here are some important missing pieces in the HFpEF
uzzle, and the findings of Ather et al. provide potentially
ritical insight.
See page 998
Ather et al. (1) used the U.S. Department of Veterans
Affairs External Peer Review Program database, which had
EF measurements in more than 17,000 ambulatory patients
with HF. Among these, they found 9,442 patients who had
EFs measured within 1 year before or 3 months after HF
diagnosis. Those with preserved EFs had more noncardiac
comorbidities (4 on average) than those with reduced EF.
Patients with HFpEF were overrepresented among those
with the greatest numbers of noncardiac comorbidities.
During 2-year follow-up, patients with HFpEF had more
noncardiovascular hospitalizations and fewer HF-related
hospitalizations than those with HFrEF. However, in both
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Sciences; and is employed by Wake Forest Health.groups, non-HF hospitalizations dominated and were 3
times greater in patients with HFpEF and 2 times greater in
those with HFrEF than HF hospitalizations. Cause-specific
mortality was not reported, but several noncardiac comor-
bidities were independent predictors of total mortality and
were similar in both groups, except chronic pulmonary
disease, which was a stronger predictor in patients with
HFpEF.
Previous studies have established that elderly patients
hospitalized with a primary diagnosis of HF often have
multiple noncardiac comorbidities (5.5 on average) (2).
These patients have frequent rehospitalizations, resulting in
high health care costs and patient burden. Importantly,
nearly two-thirds of their subsequent hospitalizations are
non-HF-related, and approximately 50% are noncardiac
(3,4). Furthermore, the majority of patients with HFpEF
(55%) die from noncardiovascular causes (5).
The implications of these data for understanding HFpEF
are profound. As Ather et al. (1) point out, they might help
explain the neutral outcomes of the large HFpEF trials to
date. In the I-PRESERVE (Irbesartan in Heart Failure
With Preserved Ejection Fraction) trial, although many
noncardiac comorbidities were exclusions from the trial,
approximately 50% of events during follow-up were non-
cardiac (6). In the PEP-CHF (Perindopril in Elderly
People With Chronic Heart Failure) trial, there was a
strong trend toward improved outcomes at 1 year that was
absent at long-term follow-up, possibly because of the
influence of competing comorbidities.
Improving HF outcomes in elderly patients, regardless of
EF, has proven difficult. Several recently reported trials of
promising intervention strategies, including telemonitoring,
novel strategies for dosing of loop diuretics, brain natriuretic
peptide agonists, and long-term disease management, have
had disappointing results. Importantly, these interventions
were highly disease specific, as they were in the HFpEF
trials, and assumed that outcomes would be predominantly
cardiovascular and would be driven solely by cardiovascular-
specific mechanisms. However, the data from Ather et al.
(1) and many other sources uniformly do not support this
assumption.
This important information suggests that a key to im-
proving outcomes in elderly patients with HFpEF is em-
bracing and addressing their multiple comorbidities. Some
might retort that this is not the cardiologist’s job. However,
if we want to improve outcomes in this disorder, which
accounts for the majority of patients with HF, we must lead
the effort and develop new strategies. Our specialty has a
strong heritage of doing so. About 50 years ago, angiogra-
phy was a skill primarily of radiologists. About 30 years ago,
cardiologists entered the domain previously exclusive to
hematologists and made major advances in thrombolysis.
Others may reply that we already do a fine job of treating
comorbidities. However, the published outcomes data do
not support that contention.
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March 13, 2012:1006–7 Outcomes in Patients With HFpEFHow might this knowledge regarding noncardiac comor-
bidities lead to the development of new, innovative strate-
gies to improve outcomes in elderly patients with HFpEF?
Recognition is a first step. Physicians who treat these
patients will understand that HF in an elderly patient is a
marker of reduced reserve capacity, not only in the cardio-
vascular system but also in multiple organ systems, and often
globally. Such patients also have high rates of frailty, which
can be measured quickly, objectively, and reproducibly and
has strong independent prognostic power (7). Furthermore,
disease-specific (HF) therapy alone may result in short-term
improvement but may have only a modest impact on overall
long-term outcomes. Therefore, a more comprehensive
approach is needed.
Years ago, inpatient geriatric assessment units, staffed by
multidisciplinary teams, were developed and shown in
prospective trials to improve key outcomes in elderly pa-
tients with acute medical syndromes. This provides cardi-
ologists a template for a comprehensive management ap-
proach in elderly patients with HF. Cardiologists could also
partner with geriatricians to co-lead multidisciplinary teams.
This model has been successful after orthopedic surgery in
the very elderly. Both models would be facilitated by
sequestration of HF patients to specific geographic units
within the hospital.
Frequently, discharges are poorly planned, transitions to the
outpatient setting are hastily arranged, the range of outpatient
options is narrow, home health care is underused and ineffec-
tive, community support is thin, and follow-up care is frag-
mented and disjointed. These issues affect all patients, but in
elderly, frail patients with multiple complex disorders and
reduced reserve, the result is predictably poor outcomes. Cre-
ative approaches need to be developed to fill these critical gaps.
After hospital discharge, elderly patients with HF remain
frail and have prolonged skeletal muscle dysfunction that
impairs mobility, which is a major risk factor for readmis-
sion, falls, pneumonia, and death (7). However, HF is not
an approved indication for cardiac rehabilitation. Further-
more, nearly all exercise rehabilitation trials in HF were
conducted in patients who had not had recent hospitaliza-
tions. Yet these are the patients at greatest risk. Innovative
strategies to address frailty and promote early mobility and
comprehensive rehabilitation are needed, along with the
trials to systematically test them.
Finally, future trials should recruit patients and assess out-
comes that faithfully reflect the disorder in the population (8).
or HFpEF, patients in the community are overwhelmingly
ery elderly (mean age 75 years), predominantly women
about 70%), and have 4 or 5 noncardiac comorbidities. No
rial to date has achieved these parameters. Patients with
ypical comorbidities and frailty should be included rather than
xcluded, as is usually done, unless clearly contraindicated. The
utcomes used in these trials should reflect total events and not
ocus solely on disease-specific outcomes, which are a minority
f events in this population. This will more accurately reflect
he impact of treatment on patient burden and health caretilization. Finally, function and quality of life should be
mphasized, because these outcomes are often as important as
urvival for elderly patients.
External pressures are mounting that may accelerate
ptake of these data. Because of its high cost, the Centers
or Medicare and Medicaid Services (CMS) has designated
F as 1 of only 3 specific diagnoses to receive hypercritical
ttention. HF outcomes are now publicly reported by CMS
or every hospital. Multiple demonstration programs have
een planned or implemented by CMS to reduce HF
ospitalizations. Beginning in 2012, CMS will penalize
ospitals with below-average total outcomes in their pa-
ients with HF, including subsequent non-HF rehospital-
zations, by reducing their total payments for all diagnoses
n all patients admitted to their hospitals. This will place
everal million dollars at risk annually for individual hospi-
als. Successful hospitals will appreciate that most rehospi-
alizations in patients with HF are non-HF-related and will
se these data to develop new strategies. Others will
ontinue to pursue the diminishing returns from strategies
ased solely on disease-specific management.
It seems paradoxical that in patients with “heart” failure,
he majority of outcomes are not only non-HF, they are
oncardiovascular. As we have in the past, cardiologists
hould take a leadership role in addressing this problem and
se these data to develop new strategies to improve out-
omes in the large and growing segment of the population
ith HFpEF.
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